Summary Testicular function was studied in 40 males treated in childhood for Hodgkin's disease at St Bartholomew's Hospital, and the Hospital for Sick Children, London, between 1971-1985. All patients were 16 years or over at evaluation, and off treatment more than 6 years. Basal FSH, LH and testosterone levels were measured. Testicular size was measured using a Prader orchidometer, and all patients were offered a seminal analysis. Twenty-eight patients were treated with chemotherapy, usually ChlVPP. Twenty-one also had radiotherapy, five below the diaphragm. Twelve patients were treated with radiotherapy alone (five below the diaphragm). Twenty-six of 28 patients treated with chemotherapy and three of five patients treated with radiotherapy alone below the diaphragm have elevated basal FSH levels, and 18 of these also have elevated basal LH levels. Median testicular volume is 11 ml (range 5-25 ml). Eleven With a current 5 year event free survival of 90%, there is increasing interest in the late effects of treatment in patients with Hodgkin's disease. Decreased sitting height due to extended field irradiation including the spine (Wilimas et al., 1980) and abnormalities of thyroid function after neck radiotherapy have been well documented (Shalet et al., 1977). Infertility appears to be almost inevitable in adult males with Hodgkin's disease treated by six or more courses of MOPP or MVPP (mustine, vincristine/vinblastine, procarbazine, prednisolone) (Whitehead et al., 1982a) . Chemotherapy induced testicular damage in patients treated for Hodgkin's disease in childhood was first reported by Sherins et al., in 1978 . Whitehead et al. (1982b reported 15 males treated with MOPP for Hodgkin's disease in childhood and concluded that severe testicular damage is common, with azoospermia, but normal pubertal development. More recently Bramswig et al. (1990) evaluated testicular function in 75 boys treated for Hodgkin's disease with involved or extended field irradiation and chemotherapy with OPPA (vincristine, prednisone, procarbazine, doxorubicin) or COPP (cyclophosphamide, vincristine, prednisone, procarbazine). Testicular dysfunction was observed in boys treated before as well as during puberty. Abnormal basal FSH/LH levels were found more frequently in patients who had received higher cumulative doses of chemotherapy.
With a current 5 year event free survival of 90%, there is increasing interest in the late effects of treatment in patients with Hodgkin's disease. Decreased sitting height due to extended field irradiation including the spine (Wilimas et al., 1980) and abnormalities of thyroid function after neck radiotherapy have been well documented (Shalet et al., 1977 ). Infertility appears to be almost inevitable in adult males with Hodgkin's disease treated by six or more courses of MOPP or MVPP (mustine, vincristine/vinblastine, procarbazine, prednisolone) (Whitehead et al., 1982a) . Chemotherapy induced testicular damage in patients treated for Hodgkin's disease in childhood was first reported by Sherins et al., in 1978 . Whitehead et al. (1982b reported 15 males treated with MOPP for Hodgkin's disease in childhood and concluded that severe testicular damage is common, with azoospermia, but normal pubertal development. More recently Bramswig et al. (1990) evaluated testicular function in 75 boys treated for Hodgkin's disease with involved or extended field irradiation and chemotherapy with OPPA (vincristine, prednisone, procarbazine, doxorubicin) or COPP (cyclophosphamide, vincristine, prednisone, procarbazine) . Testicular dysfunction was observed in boys treated before as well as during puberty. Abnormal basal FSH/LH levels were found more frequently in patients who had received higher cumulative doses of chemotherapy.
We have studied testicular function in 40 males treated in childhood for Hodgkin's disease with chemotherapy (usually chlorambucil, vincristine, procarbazine, prednisolone -ChlVPP) (Robinson et al., 1984) and/or radiotherapy to assess the effect of this treatment on subsequent fertility. range 6-18 years). Basal FSH, LH and testosterone levels were measured. FSH and LH levels were measured by standard immunoradiometric assays with intra-inter-assay coefficient of variation (CV) of < 5% for both assays. Testosterone was measured by radioimmunoassay with a CV of <5%. Testicular size was measured using a Prader orchidometer, and all patients were given the opportunity to have a seminal analysis performed.
For the purpose of this study we defined abnormal testicular function using the following criteria. Germ cell dysfunction was considered present if basal FSH level was raised above 8 u l-1'. Confirmatory evidence for this was a low testicular volume (<15ml, Zachmann et al., 1974) , and a low sperm count. Leydig cell dysfunction was considered present if basal LH level was raised above 10ul-' with or without a low testosterone level (<9nmoll1'). Table  III) had FSH levels measured before or during puberty and more than 1 year off treatment. All had normal levels which subsequently became elevated post puberty ( Figure 1 ). Sixteen patients also have elevated basal LH levels greater than 10.0 u l-1, with a median of 12.3 u 1-, range 10.1-24.0 u l-' (upper limit of normal lOu l-1). Eighteen patients have had serial LH measurements (Table III) . Four patients (case numbers 4, 7, 12, 15) have always had normal levels. Two patients (2, 18) initially had elevated LH levels 2 years and 4 years 6 months off treatment respectively, which subsequently returned to normal. Four patients (3, 5, 9, 17) have had persistently elevated levels and eight patients (1, 6, 8, 10, 11, 13, 14, 16) all except one of whom (1) were post pubertal, initially had normal LH levels which have subsequently become elevated with increasing time from the end of treatment (Figure 2 Schwartz (1990) pointed out, the reported fathering of a child is not necessarily conclusive proof of fertility. None of the other patients have children.
Radiotherapy
Of 12 patients who were treated with radiotherapy alone, seven had radiotherapy to sites above the diaphragm, and all have normal FSH, LH and testosterone levels, and normal testicular volumes. One patient who requested a seminal analysis has a normal sperm count.
Four patients had radiotherapy alone to sites below the diaphragm and one patient had radiotherapy above and below the diaphragm. Three patients received 3,500 cGy to an inverted Y field, all have elevated FSH levels and two have elevated LH levels. One of these patients initially had a normal FSH level which became elevated during puberty (Figure 1 ). Testosterone levels are normal, but all patients have small testes -12 ml or less. One patient has had a seminal analysis and he is severely oligospermic with a sperm ei-e CeW eN-0 oo FSH, LH and testosterone levels, but one has small testes (8 ml, 10 ml). For nine of the total of ten patients who received radiotherapy below the diaphragm (five patients treated by radiotherapy alone and five treated by a combination of radiotherapy and chemotherapy), it is not possible to estimate the dose to the testes which are out of the primary beam and further protected by a scrotal lead shield. However, one patient treated with radiotherapy alone, 3,500 cGy to an inverted Y field with a further 500 cGy to the right inguinal region, had a measured total scrotal dose of 456 cGy in 20 fractions over 28 days. At that time he had bilaterally undescended testes and subsequently had a right orchidopexy. Testicular volumes are 2 ml right and 10 ml left.
Discussion
A number of previous studies have reported on reproductive function following treatment for Hodgkin's disease in childhood with MOPP (Whitehead et al., 1982b; Ortin et al., 1990) and OPPA/COPP (Bramswig et al., 1990) .
We have reported here 40 males treated for Hodgkin's disease, 28 of whom received combination chemotherapy, mostly ChlVPP. Of these 28 patients, 26 (93%) have elevated basal FSH levels, indicating damage to seminiferous tubules. Seventeen of 27 patients have testicular volumes 12 ml or less, indicating reduced testicular size, normal adult testicular volume being equal to or greater than 15 ml (Zachmann et al., 1974) . Eleven of 12 patients who have had a seminal analysis are azoospermic, the other patient being oligospermic. This indicates a high incidence of damage to the germinal epithelium in patients treated with this regimen, both before or during puberty. The only patient who does not appear to have any impairment of gonadal function received only three courses of ChlVPP at the age of 4 years 10 months.
The damage caused to the gonad is not just a function of the chemotherapy received. Three of five patients treated with radiotherapy alone, below the diaphragm, have evidence of impairment of gonadal function as shown by elevated FSH levels in three associated with elevated LH levels in two patients. All three have small testes and one who has had a seminal analysis is oligospermic, 16 years off treatment. There is no evidence of recovery of function up to 17 years from diagnosis. This is similar to the Stanford experience (Ortin et al., 1990) .
All patients treated with chemotherapy and/or radiotherapy below the diaphragm having been advised of the possibility of infertility were given the opportunity to have a seminal analysis. However, only 13 patients so far have undergone this investigation. The remainder do not wish to know their fertility status at the present time. The desire for information was not related to the age of the patient as the median age of the two groups is the same.
All patients with azoospermia or oligospermia have raised FSH levels, confirming the close correlation between raised FSH levels and germ cell damage (Briimswig et al., 1990; Siimes & Rautonen, 1990 ).
This study includes 18 patients who have had serial FSH and LH measurements. It has been suggested that serial FSH levels might help to determine whether the damage sustained by the germinal cell epithelium is in the process of healing (FSH decreasing) , stable, or progressive (FSH increasing) (Schwartz, 1990) . If basal FSH truly reflects damage to the germinal cell epithelium, then the results shown in Table III do not give grounds for optimism regarding healing of chemotherapy induced damage, with elevated levels persisting up to 17 years from cessation of treatment, suggesting that the damage to the germinal epithelium is irreversible. Figure  1 demonstrates graphically that FSH levels are unhelpful in predicting testicular damage in pre pubertal and peripubertal boys, confirming the findings of Green et al. (1981) .
All the patients in the study progressed through puberty satisfactorily with the normal development of secondary sexual characteristics which would indicate normal Leydig cell function at that time. None of the patients had gynaecomastia unlike the boys in Sherins study (Sherins et al., 1978) . However, 16/28 treated with chemotherapy and 2/5 treated with radiotherapy alone (inverted Y 3,500 cGy) have elevated serum LH levels, first noted 5-19 years from diagnosis. As all testosterone levels are in the normal range, this suggests that increased LH secretion is necessary to maintain normal testosterone production. However with the fall in testosterone levels noted in several patients, premature Leydig cell failure is a real possibility. Continuing follow up of these patients with annual measurement of FSH/LH and testosterone levels is needed to further elucidate the natural history of the impairment of gonadal function.
Appropriate counselling of boys treated with ChlVPP chemotherapy and/or radiotherapy below the diaphragm with regard to their reproductive potential is essential. However, it is important to remember that FSH levels in pre-and peri-pubertal boys are unreliable as indicators of gonadal damage. Although FSH level and testicular size in patients who are post pubertal may give a good indication of damage to the germinal epithelium, seminal analysis still remains the definitive test of an individual's reproductive potential.
Annual follow up, for many years, will be needed before the consequences of ChlVPP-induced damage are fully revealed. There is an urgent need for chemotherapy regimens effective in Hodgkin's disease which are less damaging to the gonads.
